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Interaction between genetic 
predisposition, smoking, 
and dementia risk: 
a population‑based cohort study
Na Zhang1,9, Janice M. Ranson2, Zhi‑Jie Zheng1,9, Eilis Hannon2, Zhenwei Zhou3, 
Xuejun Kong4,5, David J. Llewellyn2,6, Daniel A. King7 & Jie Huang 1,8,9*
We evaluated whether the association between cigarette smoking and dementia risk is modified by 
genetic predisposition including apolipoprotein E (APOE) genotype and polygenic risk (excluding the 
APOE region). We included 193,198 UK Biobank participants aged 60–73 years without dementia at 
baseline. Of non‑APOE‑ε4 carriers, 0.89% (95% CI 0.73–1.08%) current smokers developed dementia 
compared with 0.49% (95% CI 0.44–0.55%) of never smokers (adjusted HR 1.78; 95% CI 1.39–2.29). 
In contrast, of one APOE‑ε4 allele carriers, 1.69% (95% CI 1.31–2.12%) current smokers developed 
dementia compared with 1.40% (95% CI 1.25–1.55%) of never smokers (adjusted HR 1.06; 95% CI 
0.77–1.45); of two APOE‑ε4 alleles carriers, 4.90% (95% CI 2.92–7.61%) current smokers developed 
dementia compared with 3.87% (95% CI 3.11–4.74%) of never smokers (adjusted HR 0.94; 95% CI 
0.49–1.79). Of participants with high polygenic risk, 1.77% (95% CI 1.35–2.27%) current smokers 
developed dementia compared with 1.05% (95% CI 0.91–1.21%) of never smokers (adjusted HR 1.63; 
95% CI 1.16–2.28). A significant interaction was found between APOE genotype and smoking status 
(P = 0.002) while no significant interaction was identified between polygenic risk and smoking status 
(P = 0.25). APOE genotype but not polygenic risk modified the effect of smoking on dementia risk.
Dementia is one of the major causes of disability and dependency in later  life1. Both genetic and lifestyle factors 
contribute to the development of  dementia2,3. Apolipoprotein E (APOE) gene polymorphism is strongly associ-
ated with late-onset Alzheimer Disease (AD)4,5. It also plays a role in risk for vascular  dementia6, Lewy body 
 dementia7,8 and frontotemporal  dementia9. There are three APOE isoforms, APOE2, APOE3, APOE4, encoded 
by 3 common alleles, ε2, ε3 and ε4. Compared to the reference ε3 allele, ε2 is protective against AD, while ε4 
is the largest known genetic risk factor of late-onset sporadic AD in a variety of ethnic  groups10. In European 
populations, a single ε4 allele increases an individual’s risk for AD by three-fold11, while two ε4 alleles increase 
the rate by nearly 30-fold by 75 years of age. APOE ε4 carriers are also more likely to develop other types of 
 dementia9,12–14. A polygenic risk score (PRS) indicates cumulative genetic propensity using multiple risk alleles 
identified by genome-wide association studies (GWAS)15. Individuals with higher PRS are more likely to develop 
 dementia16,17, and may also have an earlier onset of the  disease18.
Compelling evidence suggests that tobacco smoking is associated with a higher risk of  dementia14,19–21. In 
addition to an independent effect, smoking may interact with genetic risk factors for dementia. However, prior 
findings have been inconsistent. Evidence from the population-based Rotterdam study suggested that smoking 
was only associated with dementia risk in ε4 allele non-carriers22,23 whereas a population-based study in Fin-
land found that smoking increased risk of dementia among ε4 allele  carriers24. Furthermore, no studies to our 
knowledge have examined the gene-smoking interaction on dementia risk at a genome-wide level. Here, we used 
prospective data from a large population-based study to examine the interaction between genetic predisposi-
tion including APOE genotype and polygenic risk and smoking in contributing to the risk of dementia. It aims 
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to clarify whether dementia risk reduction strategies incorporating smoking cessation are likely to be effective 
regardless of genotype, or conversely are only likely to be effective in targeted groups.
Methods
Study design, data sources and participants. We conducted a population-based retrospective cohort 
study using UK Biobank data. The UK Biobank (UKB) cohort consists of over 500,000 adults aged 37–73 years 
who were recruited from 22 research centers across the UK between 2006 and  201025. Our analytic sample was 
restricted to individuals with White British ancestry because APOE ε4 allele frequencies vary between different 
 populations26 and the polygenic risk score for Alzheimer disease was based upon GWAS results from White par-
ticipants. Our sample was also limited to those at least 60 years old at baseline because our study was focused on 
the prediction of sporadic late-onset dementia. Participants younger than 60 years (n = 285,022), without ethnic 
background information (n = 1182) or not White British (n = 17,400), with missing APOE genotype information 
(n = 5324) or ε1 allele (n = 25), with unmatched self-reported sex and genetic sex (n = 121) and excessive relatives 
(n = 88), and with dementia at baseline or prior to recruitment (n = 145) were excluded (Supplementary Fig. S1).
Ethics declarations. This study was conducted according to the Declaration of Helsinki. The generic ethi-
cal approval was obtained by UK Biobank from the NHS National Research Ethics Service (approval letter dated 
June 17th 2011, Ref 11/NW/0382). All participants provided written informed consent to participate in the UK 
Biobank.
APOE haplotype. We first identified each subject’s APOE haplotype based on pre-phasing the whole chro-
mosome 19, using the EAGLE software  tool27. We characterized the haplotype by race, by ethnicity, and by other 
demographic parameters. We further confirmed the inferred APOE haplotype in 48,855 samples with exome 
sequencing data. We excluded those predicted with ε1 haplotypes and generated a factor variable with six pos-
sible combinations of ε2 to ε4, namely, ε2ε2, ε2ε3, ε2ε4, ε3ε3, ε3ε4, ε4ε4. The six APOE genotypes were classified 
into three categories: zero ε4 allele (ε2ε2, ε2ε3, ε3ε3), one ε4 allele (ε3ε4, ε4ε4), and two ε4 alleles (ε4ε4) carriers.
Polygenic risk score. A polygenic risk score (PRS) was calculated using the same methods documented 
in a previous  study16. In brief, 249,273 single-nucleotide polymorphisms (SNPs) (excluding the APOE gene) 
with a P value less than 0.5 for association with Alzheimer disease (AD) were used to compute the PRS. The 
number of risk alleles carried at each SNP were weighted by its effect size in GWAS for  AD28, then summed and 
z-standardized16. In the present study, the PRS was divided into quintiles and then categorized into low, middle, 
and high polygenic risk according to lowest quintile, 2–4 quintiles and highest quintile, respectively.
Dementia diagnosis. Dementia was identified using algorithmically-defined dementia outcomes provided 
by UKB. It includes primary care information with linked data from hospital admissions and death  registries29. 
The hospital and mortality data are coded using the International Classification of Disease version 10 (ICD-10). 
The algorithms were developed to identify individuals with ICD-10 codes for any cause of dementia and the 
subtypes including Alzheimer’s disease, vascular dementia and frontotemporal dementia.
Tobacco smoking. Smoking status was assessed using a touchscreen questionnaire, and defined as (1) 
never smokers, if individuals specified that they either never smoked tobacco, or just tried once or twice in the 
past but less than 100 cigarettes over their lifetime; (2) former smokers, if they smoked on most or all days, or 
occasionally, or just tried once or twice in the past with more than 100 cigarettes over their lifetime; (3) current 
smokers, if they smoked on most or all days, or occasionally at present.
Covariates. Covariates measured at the initial assessment visit were incorporated in the analyses as potential 
confounders. Sociodemographic variables comprised age, sex, educational attainment and deprivation quintiles. 
Educational attainment was grouped into two categories based on a previous  study30. Townsend deprivation 
 score31 was categorized into least (lowest quintile), intermediate (quintiles 2–4), and most (highest quintile) 
deprived. Body mass index (BMI) was grouped into four categories according to WHO  guidelines32: under-
weight (BMI < 18.5  kg/m2); normal weight (18.5–24.9  kg/m2); overweight (25.0–29.9  kg/m2); obese (at least 
30.0 kg/m2). Alcohol consumption was categorized into never, former and current drinker. Family history of 
dementia is a composite risk factor reflecting both genetic and non-genetic risks. Its relevant effects are separa-
ble from that of APOE ε4  allele33, and could strengthen the prediction power of the model together with  PRS34. 
Thus, family history is incorporated as a covariate in the model.
Statistical analysis. Cox proportional hazards regression model was used to determine risk of incident 
dementia during follow-up. Participants who did not develop dementia during the follow-up were censored 
in this study. Two multiplicative terms APOE genotype x smoking and polygenic risk x smoking were added into 
independent Cox models to assess APOE genotype-by-smoking and polygenic risk-by-smoking interactions, 
respectively. We compared the full model (with the interaction term of APOE genotype-by-smoking or polygenic 
risk-by-smoking) with a reduced model (without the interaction term) using a likelihood ratio test. Besides mul-
tiplicative interaction, we also evaluated an additive interaction effect by calculating the relative excess risk due 
to interaction (RERI), attributable proportion (AP) and synergy index (S). All models were adjusted for age, sex, 
educational attainment, deprivation quintile, BMI, parental family history of dementia and the first five genetic 
principal components derived from genetic  data35 for population stratification. Effects were estimated by haz-
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ards ratios (HR) with 95% confidence intervals (95% CI). The proportional hazards assumption was checked for 
each Cox model by measuring Schoenfeld residuals, and results indicated no potential violation of the assump-
tion. We used complete case  analysis since the proportion of missing data for main variables was less than 
5%. We conducted three sensitivity analyses. First, we stratified the sample by sex and repeated the reduced 
model and full model. Second, we adjusted for self-reported depression assessed by the two-item Patient Health 
Questionnaire (PHQ-2)36. The range of PHQ-2 score is from 0 to 6 with a score ≥ 3 indicative of self-reported 
depression. Additionally, we conducted the main analyses after excluding individuals within three years of fol-
low-up to reduce the possibility of reverse causation bias. Although some overlap in the mechanisms leading to 
dementia would be expected between Caucasians and non-Caucasians, we didn’t conduct a sensitivity analysis 
among non-White participants due to the insufficient cases in UKB. We used R version 4.0.2 and R packages 
survival version 3.2-7, survminer version 0.4.8, epiR version1.0-15, and ggplot2 version 3.3.2 for analyses, and a 
two-tailed P value < 0.05 was considered statistically significant.
Results
Baseline characteristics. 193,198 participants were included in the analysis. The mean (SD) age of the par-
ticipants at baseline was 64.1 (2.9) years, and 101,322 (52.4%) were female. They were followed up for 1,700,886 
person-years (median [interquartile range] follow-up, 9.0 [8.3–9.7] years). One thousand seven hundred and 
eighty-eight cases of incident all-cause dementia were identified. Baseline characteristics of the participants are 
summarized in Table 1.
APOE genotype, polygenic risk and dementia risk. Dementia risk was significantly higher among 
APOE-ε4 allele carriers compared to non-ε4 allele carriers (Supplementary Fig. S2). Specifically, two APOE-ε4 
alleles carriers were at greatest risk of dementia followed by one-ε4 allele carriers compared with non-carriers, 
with an adjusted hazard ratio (HR) of 7.63 (95% confidence interval [CI] 6.46–9.01) and 2.47 (95% CI 2.22–
2.76), respectively (Table 2). The strength of the associations was slightly attenuated after additionally adjusting 
for smoking status with HR of 7.53 (95% CI 6.36–8.91) for two-ε4 allele carriers and 2.45 (95% CI 2.20–2.74) 
for one-ε4 allele carriers (Supplementary Fig. S3). Individuals with intermediate and high polygenic risk were at 
greater risk of developing dementia (Supplementary Fig. S2). The adjusted hazard ratio (HR) of dementia was 
1.53 (95% CI 1.29–1.81) for individuals with high polygenic risk and 1.28 (95% CI 1.10–1.49) for those with 
intermediate polygenic risk (Table 2). Strength of the associations between polygenic risk and dementia risk 
were slightly stronger after additionally controlling for smoking status, with HR of 1.55 (95% CI 1.31–1.83) for 
high polygenic risk and 1.29 (95% CI 1.11–1.50) for intermediate polygenic risk individuals (Supplementary 
Fig. S3).
Smoking status with dementia risk. Dementia risk was significantly associated with smoking (Sup-
plementary Fig. S2; Table 2). Current and former smokers had a higher risk of dementia than those who never 
smoked (HR 1.36; 95% CI 1.13–1.63) and HR 1.20; 95% CI 1.07–1.34, respectively). The hazards ratio of demen-
tia risk for current and former versus never smokers remained nearly unchanged after the additional adjustment 
of APOE genotype and polygenic risk (HR 1.37; 95% CI 1.14–1.65 and HR 1.19; 95% CI 1.06–1.32, respectively) 
(Supplementary Fig. S3).
Interaction between APOE genotype and smoking on dementia risk. Cumulative incidence 
of dementia according to APOE genotype and smoking status is shown in Fig. 1a. Among participants with 
zero APOE-ε4 allele, 0.89% (95% CI 0.73–1.08%) current and 0.64% (95% CI 0.58–0.71%) former smokers 
developed dementia compared with 0.49% (95% CI 0.44–0.55%) of never smokers (adjusted HR 1.78; 95% CI 
1.39–2.29; P = 0.01 and HR 1.23; 95% CI 1.05–1.46; P < 0.001, respectively) (Fig. 1a; Table 3). In contrast, among 
one APOE-ε4 allele carriers, 1.69% (95% CI 1.31–2.12%) current and 1.62% (95% CI 1.46–1.80%) former smok-
ers developed dementia compared with 1.40% (95% CI 1.25–1.55%) of never smokers (adjusted HR 1.06; 95% 
CI 0.77–1.45; P = 0.73 and HR 1.11; 95% CI 0.94–1.32; P = 0.21, respectively); of two APOE-ε4 alleles carriers, 
4.90% (95% CI 2.92–7.61%) current and 5.31% (95% CI 4.34–6.40%) former smokers developed dementia com-
pared with 3.87% (95% CI 3.11–4.74%) of never smokers (adjusted HR 0.94; 95% CI 0.49–1.79; P = 0.84 and HR 
1.32; 95% CI 0.96–1.81; P = 0.09, respectively) (Fig. 1a; Table 3). There was significant negative multiplicative 
interaction between current smoking and one APOE-ε4 allele carriers (HR 0.54; 95% CI 0.36–0.80; P = 0.002) 
(Table 4). However, the additive interaction between current smoking and one APOE-ε4 allele carriers was not 
significant (RERI − 0.85, 95% CI − 1.84–0.13; AP − 0.30, 95% CI − 0.71–0.12; S 0.68, 95% CI 0.42–1.11). Neither 
multiplicative interaction (HR of 0.53 [95% CI 0.27–1.05]; P = 0.07) nor additive interaction (RERI − 0.93, 95% 
CI − 5.95–4.10; AP − 0.12, 95% CI − 0.82–0.58; S 0.88, 95% CI 0.43–1.81) between current smoking and two 
APOE-ε4 alleles carriers was significant (Table 4).
Interaction between polygenic risk and smoking status on dementia risk. Cumulative incidence 
of dementia according to polygenic risk category and smoking status is shown in Fig. 1b. Of individuals with low 
polygenic risk, 0.94% (95% CI 0.64–1.33%) current and 0.67% (95% CI 0.55–0.80%) former smokers developed 
dementia compared with 0.59% (95% CI 0.49–0.71%) of never smokers (adjusted HR 1.28; 95% CI 0.79–2.07; 
P = 0.32 and HR 1.04; 95% CI 0.78–1.40; P = 0.77, respectively) (Fig. 1b; Table 3). In contrast, of individuals with 
intermediate polygenic risk, 1.05% (95% CI 0.86–1.28%) current and 1.01% (95% CI 0.93–1.11%) former smok-
ers developed dementia compared with 0.80% (95% CI 0.72–0.87%) of never smokers (adjusted HR 1.25; 95% CI 
0.97–1.60; P = 0.09 and HR 1.23; 95% CI 1.06–1.41; P = 0.01, respectively); and of individuals with high polygenic 
risk, 1.77% (95% CI 1.35–2.27%) current and 1.34% (95% CI 1.17–1.53%) former smokers developed dementia 
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compared with 1.05% (95% CI 0.91–1.21%) of never smokers (adjusted HR 1.63; 95% CI 1.16–2.28; P = 0.005 
and HR 1.21; 95% CI 0.97–1.50; P = 0.09, respectively) (Fig. 1b; Table 3). Neither multiplicative (HR of 1.17 [95% 
CI 0.66–2.08]; P = 0.58) nor additive interaction (RERI 0.49, 95% CI − 0.43–1.42; AP 0.22, 95% CI − 0.15–0.58; 
S 1.62, 95% CI 0.59–4.44) between current smoking and high polygenic risk was significant (Table 4). Moreover, 
there was no significant multiplicative (HR of 0.92 [95% CI 0.54–1.57]; P = 0.77) or additive interaction (RERI 
− 0.05, 95% CI − 0.77–0.67; AP − 0.03, 95% CI − 0.51–0.44; S 0.91, 95% CI 0.26–3.24) between current smoking 
and intermediate polygenic risk (Table 4).
Sensitivity analyses. The association between genetic predisposition and dementia risk was similar 
between men and women (Supplementary Fig. S4). However, current and former smoking were associated with 
Table 1.  Baseline characteristics of participants. a Other qualifications indicate without a college or university-
level degree. b Percentages may not sum to 100 because of rounding.
No incident dementia
(n = 191,410) (%)
Incident dementia
(n = 1788) (%)b
Age, mean (SD), years 64.1 (2.8) 65.8 (2.7)
Sex
Female 100,525 (52.5) 797 (44.6)
Male 90,885 (47.5) 991 (55.4)
Educational attainment
Higher education 47,905 (25.0) 322 (18.0)
Other  qualifications‡ 141,100 (73.7) 1416 (79.2)
Missing 2405 (1.3) 50 (2.8)
Deprivation quintile
1 (Least deprived) 38,317 (20.0) 317 (17.7)
2–4 (Intermediate deprived) 114,828 (60.0) 969 (54.2)
5 (Most deprived) 38,105 (19.9) 501 (28.0)
Missing 160 (0.1) 1 (0.1)
Number of APOE ε4 alleles
Zero 137,642 (71.9) 817 (45.7)
One 49,458 (25.8) 763 (42.7)
Two 4310 (2.3) 208 (11.6)
Polygenic risk category
Low 38,386 (20.1) 254 (14.2)
Middle 114,861 (60.0) 1057 (59.1)
High 38,163 (19.9) 477 (26.7)
Smoking status
Never 94,979 (49.6) 771 (43.1)
Previous 80,067 (41.8) 818 (45.7)
Current 15,458 (0.1) 185 (10.3)
Missing 906 (0.5) 14 (0.8)
Alcohol-intake status
Never 7933 (4.1) 121 (6.8)
Previous 6973 (3.6) 136 (7.6)
Current 176,340 (92.1) 1526 (85.3)
Missing 164 (0.1) 5 (0.3)
Body mass index (BMI, kg/m2)
Normal 56,088 (29.3) 518 (29.0)
Underweight 809 (0.4) 15 (0.8)
Overweight 86,562 (45.2) 773 (43.2)
Obese 47,272 (24.7) 465 (26.0)
Missing 679 (0.3) 17 (1.0)
Parents who had dementia
None 146,627 (76.6) 1209 (67.6)
Father 7946 (4.2) 89 (5.0)
Mother 19,718 (10.3) 237 (13.3)
Both 1266 (0.7) 20 (1.1)
Missing 15,853 (8.3) 233 (13.0)
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greater dementia risk among women (HR 1.55; 95% CI 1.16–2.07 and HR 1.29; 95% CI 1.10–1.52, respectively) 
compared with never smokers but not in men (HR 1.25; 95% CI 0.98–1.59 and HR 1.10; 95% CI 0.95–1.28, 
respectively). There was significant multiplicative interaction between smoking status and APOE genotype 
among women (interaction P = 0.01) while no additive interaction was detected (Supplementary Table S1). Nei-
ther multiplicative interaction nor additive interaction between smoking status and polygenic risk was observed 
on dementia risk among women. For men, there was significant additive interaction (RERI 3.81, 95% CI 0.67–
6.96; AP 0.40, 95% CI 0.14–0.66; S 1.81, 95% CI 1.09–3.01) between one APOE-ε4 allele carriers and former 
smoking on dementia risk while non-significant multiplicative interaction was identified (HR 1.49; 95% CI 
0.92–2.41) (Supplementary Table S2). The interaction between smoking and genetic predisposition was similar 
with the main analyses after additionally adjusting for self-reported depression (Supplementary Table S3) and 
after excluding participants followed up for less than three years (Supplementary Table S4).
Table 2.  Risk of incident dementia according to APOE genotype, polygenic risk and smoking status. Model 
1 and Model 2 were adjusted for age, sex, educational attainment, deprivation quantile, BMI, alcohol-intake 
status, parental dementia status and 5 principal components of ancestry, respectively. HR hazard ratio, CI 
confidence interval.
No. of dementia cases/no. of person at risk HR 95% CI P value
Model 1
Number of APOE ε4 alleles
 Zero 817/138,459 Reference Reference Reference
 One 763/50,221 2.47 2.22–2.76  < 0.001
 Two 208/4518 7.63 6.46–9.01  < 0.001
Polygenic risk category
 Low 254/38,640 Reference Reference Reference
 Middle 1057/115,918 1.28 1.10–1.49 0.001
 High 477/38,640 1.53 1.29–1.81  < 0.001
Model 2
Smoking status
 Never 771/955,750 Reference Reference Reference
 Previous 818/80,885 1.20 1.07–1.34 0.001
 Current 185/15,643 1.36 1.13–1.63 0.001
Figure 1.  Cumulative incidence of dementia according to genetic predispostion and smoking status. Shown are 
cumulative incidence of dementia according to APOE genotype, polygenic risk category, and smoking status. 
The I bars represent 95% confidence intervals.
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Discussion
To our knowledge, this study is the first large population-based analysis exploring the interaction between APOE, 
polygenic risk and smoking in relation to dementia risk. APOE genotype modified the association between 
smoking and dementia risk. However, there was no interactive effect of current or past smoking with polygenic 
risk on the risk of dementia. Carriers of two ε4 alleles (APOE ε4ε4 genotype) had the greatest risk of developing 
dementia after adjusting for potential confounders. APOE-ε4 allele is the strongest genetic risk for late-onset 
form of Alzheimer’s disease (LOAD). Individuals with higher polygenic risk had a greater dementia risk indica-
tive of the polygenic architecture of  dementia14.
Tobacco usage may worsen cognitive function and increase risk of  dementia23,37,38. Smoking may induce cer-
ebral oxidative stress that accelerate Alzheimer disease pathology and increase its  risk39. In this large population-
based study, both current and previous smokers were at increased risk of dementia. Conversely, neither current 
nor former smokers had higher dementia risk among carriers of one or two ε4 alleles. Our study indicated that 
APOE-ε4 genotype was the strongest risk for dementia in the model adjusting for genetic predisposition and 
smoking. It increased dementia risk in a way such that the relative risk of other risk factors including smoking 
on dementia weakened in APOE ε4 heterozygotes, and even disappeared in ε4 homozygotes. APOE genotype 
modified the association between smoking and dementia risk. APOE-ε4 allele carriers who were also smokers 
demonstrated greater cortical amyloid deposition, poor auditory-verbal learning and  memory40 which might 
increase the risk of developing dementia. Our findings were in agreement with the results of two Rotterdam 
 studies22,23 that the magnitude of risk elevation seen between current smokers and never smokers was great-
est among non-carriers of the ε4 allele. However, the later Rotterdam study in 2007 concluded that there was 
no interaction between smoking status and APOE genotype on risk of  dementia23. One possible explanation 
for this inconsistency may lie in the larger sample size in our study which increases statistical power to detect 
Table 3.  Risk of incident dementia according to smoking status within each APOE genotype and polygenic 
risk category. All analyses were adjusted for age, sex, educational attainment, deprivation quantile, BMI, 
parental dementia status, and 5 principal components of ancestry. HR hazard ratio, CI confidence interval.
No. of dementia cases/no. of person at risk HR 95% CI P value
Number of APOE ε4 alleles
Zero
Smoking status
 Never 339/68,746 Reference Reference Reference
 Previous 372/57,740 1.23 1.05–1.46 0.01
 Current 101/11,321 1.78 1.39–2.29  < 0.001
One
Smoking status
 Never 346/24,781 Reference Reference Reference
 Previous 344/21,223 1.11 0.94–1.32 0.21
 Current 67/3975 1.06 0.77–1.45 0.73
Two
Smoking status
 Never 86/2223 Reference Reference Reference
 Previous 102/1922 1.32 0.96–1.81 0.09




 Never 116/19,552 Reference Reference Reference
 Previous 106/15,850 1.04 0.78–1.40 0.77
 Current 29/3075 1.28 0.79–2.07 0.32
Middle
Smoking status
 Never 456/57,324 Reference Reference Reference
 Previous 494/48,758 1.23 1.06–1.41 0.01
 Current 98/9295 1.25 0.97–1.60 0.09
High
Smoking status
 Never 199/18,874 Reference Reference Reference
 Previous 218/16,277 1.21 0.97–1.50 0.09
 Current 58/3273 1.63 1.16–2.28 0.005
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interactions. Our study demonstrated current smokers within the highest polygenic risk quintile had an increased 
risk of developing dementia compared to never smokers, whereas there was no significant association between 
current smoking and dementia risk among individuals at lower or intermediate polygenic risk. Consistent with a 
previous study that reported non-significant interaction between lifestyle and polygenic risk on dementia  risk16, 
we also found no significant multiplicative or additive interaction between smoking status and polygenic risk. Our 
sensitivity analyses showed that current and past smoking increased the dementia risk only among women, after 
adjusting for genetic predisposition and other covariates. Female smokers are more vulnerable to cardiovascular 
 disease41 which further increases their risk of dementia. APOE genotype modified the effect of smoking status on 
dementia risk among women and men in different ways. Current smoking and ε4 heterozygotes had significant 
negative multiplicative interaction while non-significant additive interaction among women. However, among 
men, past smoking and ε4 homozygotes had significant additive interaction while non-significant multiplicative 
interaction among men. It is possible that smoking status and APOE genotype have a negative multiplicative 
interaction while non-significant additive interaction or a significant positive additive interaction effect while 
non-significant multiplicative interaction since the two effects depend on different scale. The additive interaction 
is based on a risk difference scale with a larger effect while the multiplicative interaction is based on a risk ratio 
scale with a relatively smaller  effect42.
The strengths of this study include the large population-based sample, the long follow-up period, the com-
prehensive approach to investigating genetic risk, the novel investigation of interactions, the careful adjustment 
for potential confounders, and the use of sensitivity analyses to investigate the robustness of findings.
Our study also had a number of limitations: First, the algorithmically-defined dementia cases including 
both primary care information and hospital or death registry linked data used in this study is likely to include 
misclassified or misdiagnosed participants. However, the algorithm was developed to balance sensitivity and 
 specificity29. Incorporating primary care data may reduce the proportion of missed dementia cases or false nega-
tives in health or death registry records. Second, data on smoking status was addressed only once, at baseline, 
which would not capture change of these health behaviors during the follow-up. Third, although the models were 
adjusted for known potential confounders, the possibility of residual or unmeasured confounders may affect 
the results. Fourth, our study sample included individuals aged between 60 and 65 years old. The majority of 
UK Biobank participants over the age of 60 are younger than 65, and comparatively healthier than the general 
 population43. Over 9 years follow-up, there were 1788 (0.93%) incident cases in this younger group compared 
to 1231 (1.4%) incident cases among those aged greater than 65 years. Fifth, our polygenic risk score (PRS) is 
made for AD, but the outcome is any type of dementia. However, PRS for AD could predict clinical diagnosis 
Table 4.  Interactions between smoking status and genetic predisposition on dementia risk. HR, hazard ratio; 
CI: confidence interval; RERI, relative excess risk due to interaction; AP, attributable proportion; S, synergy 
index; RERI = 0; AP = 0; S = 1: no interaction; RERI > 0; AP > 0; S > 1: positive interaction; RERI < 0; AP < 0; 
S < 1: negative interaction. Dash “–”: not applicable. P value for interaction: results from likelihood ratio test 
to compare the reduced model excluding interaction term with the full model including the term. All analyses 
were adjusted for age, sex, educational attainment, deprivation quantile, BMI, parental dementia status, and 5 
principal components of ancestry.
Variables








(95% CI) P value P value for interaction
Smoking status * number of APOE 
ε4 alleles – – – – – 0.002
Never * zero – – – Reference Reference –
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of all-cause  dementia17,44. Lastly, the participants in this study was restricted to older White British adults that 
might limit the generalizability of the findings to other ethnicities.
In conclusion, this study demonstrates how genetic predisposition modifies the association between smoking 
status and dementia risk. Current smokers had a higher risk of dementia among non-APOE-ε4 allele carriers 
and among individuals within high polygenic risk. For smokers among APOE-ε4 allele carriers, the prevention 
strategies on dementia might be more effective by alleviating the negative effect of APOE ε4 allele and smoking 
via other composite measures rather than solely through smoking control.
Data availability
The data that support the findings of this study are available from the corresponding author on reasonable 
request.
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